(Q36085302)

12 August 2017

1 reference

title

Deep vein thrombosis in cancer: the scale of the problem and approaches to management (English)

1 reference

12 August 2017

1 reference

1 reference

A Falanga

1

1 reference

12 August 2017

L Zacharski

series ordinal

2

1 reference

12 August 2017

publication date

31 March 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

16

1 reference

12 August 2017

issue

5

1 reference

12 August 2017

page(s)

696-701

1 reference

Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI165

The thrombophilic state induced by therapeutic agents in the cancer patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI165

Venous Thromboembolism Associated With Long-Term Use of Central Venous Catheters in Cancer Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI165

Pathophysiology of the thrombophilic state in the cancer patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI165

Markers of Coagulation and Angiogenesis in Cancer-Associated Venous Thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI165

The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI165

Venous and arterial thrombosis in patients who received adjuvant therapy for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI165

Increased thromboembolic complications with concurrent tamoxifen and chemotherapy in a randomized trial of adjuvant therapy for women with breast cancer. National Cancer Institute of Canada Clinical Trials Group Breast Cancer Site Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI165

Symptomatic venous thromboembolism in cancer patients treated with chemotherapy: an underestimated phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI165

Prevention of venous thromboembolism in general surgical patients. Results of meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI165

Venous thromboembolism and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI165

The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI165

Importance of findings on the initial evaluation for cancer in patients with symptomatic idiopathic deep venous thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI165

Undiagnosed malignancy in patients with deep vein thrombosis: incidence, risk indicators, and diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI165

Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI165

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI165

The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI165

Risk factors for bleeding in major abdominal surgery using heparin thromboprophylaxis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI165

Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI165

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI165

How we diagnose and treat deep vein thrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI165

Low-molecular-weight heparin versus warfarin for prevention of recurrent venous thromboembolism: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI165

Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI165

Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI165

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI165

A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI165

Prognosis of Cancers Associated with Venous Thromboembolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI165

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDI165

1 reference

12 August 2017

1 reference